CD8A and neoplasm: In this study we evaluated formally the optimal binding affinity of HLA‐I‐restricted TCRs in CD4+ and CD8+ T cells by using a range of high‐affinity TCRs specific for two well‐studied and therapeutically important HLA A2‐restricted tumour antigens, NY‐ESO‐1157–165 and gp100280–288.